Drug Profile


Alternative Names: 572016; Cipatinib; GSK-572016; GW-2016; GW-572016; GW-572016F; Lapatinib ditosilate; Lapatinib ditosylate; Tycerb; Tykerb; Tyverb

Latest Information Update: 17 Jan 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; Novartis
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II Colorectal cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 10 Jan 2017 GlaxoSmithKline completes a phase II trial in Breast cancer (Combination therapy, Second-line therapy or greater) in Japan before January 2017 (UMIN000005219)
  • 01 Aug 2016 University of Kansas Medical Center completes a phase II trial for Breast cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT01283789)
  • 12 Jul 2016 GlaxoSmithKline and SOLTI Breast Cancer Research Group complete the phase II PAMELA trial in Breast cancer (Combination therapy, First-line therapy, Neoadjuvant therapy) in Spain (PO) before July 2016 (EudraCT2013-001036-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top